Pat
Cotroneo

In biotech, CFOs last about as long as a clinical trial phase. Pat Cotroneo lasted 21 years at a single company - and left only on his own terms. When FibroGen, Inc. announced his retirement in August 2021, the announcement read less like a departure and more like the closing of a chapter that had started back when the company was still largely a bet on biology.

Cotroneo joined FibroGen in 2000. He became CFO in 2008. In those 13 years between joining and stepping back from the top finance role, he watched the company transform twice - first from a private development-stage company into a publicly traded enterprise, then from a research operation into one with commercial product revenue flowing from China. He oversaw both.

San Francisco-based and life-sciences-fluent since 1987, Cotroneo built his early career at Deloitte & Touche, then moved into industry at SyStemix, Inc. and Genetic Therapy, Inc. - both eventually folded into Novartis - before landing at FibroGen at the turn of the millennium.

FibroGen's IPO in November 2014 wasn't just another biotech going public. It raised $167.7 million at a valuation of $1.04 billion - making it the largest biotech IPO by market cap since 2002. Twelve years of relative quiet, then FibroGen broke the streak.

That kind of market debut requires more than a good pipeline. It requires a CFO who can translate scientific promise into financial credibility - in the roadshow, in the prospectus, in the numbers that investors will bet on for years. Cotroneo had spent six years as CFO by then, and over a decade inside the company's financial architecture.

The IPO wasn't a single event - it was the culmination of years of financial structuring, partnership management, and investor relations work done quietly while the science competed for headlines. Cotroneo was the one making sure the balance sheet told a story the markets could believe.

Cotroneo's path to CFO was built on technical precision before it was built on strategy. Six years at Deloitte & Touche (1987-1993) gave him the foundation: the kind of accounting discipline that separates finance leaders who can read a situation from those who only know how to report on it.

From Deloitte he moved into industry, joining SyStemix, Inc. as Controller - a role that extended to Genetic Therapy, Inc., both companies operating under what would become the Novartis umbrella. Seven years in that world, from 1993 to 2000, taught him the pace of life sciences finance: the long development timelines, the milestone-driven revenue recognition, the particular nervousness of a balance sheet that can shift entirely on a single clinical readout.

He arrived at FibroGen in 2000. By the time he was named CFO in 2008, he already understood how the company's science connected to its financial obligations, its partnership structures, and its long-term capital needs. That knowledge doesn't come from an MBA. It comes from being in the room for a long time.

FibroGen has since rebranded as Kyntra Bio, sharpening its focus on oncology and rare disease. The company Cotroneo helped take public and grow to commercial stage is now pioneering treatments at what the company describes as "the frontiers of cancer biology and rare disease."

The current executive team includes CEO Thane Wettig, CFO David DeLucia, and General Counsel John Alden. The financial scaffolding Cotroneo built during his 21-year tenure underlies the enterprise that Kyntra Bio has become.

Cotroneo earned his Bachelor of Science with honors from the University of San Francisco - the same city where he would spend his entire professional career. He was recognized as a Louise M. Davies Scholar, an award that reflects both academic standing and the kind of institutional recognition that follows people who take their work seriously from the start.

The University of San Francisco, a Jesuit institution in the heart of the city, has a strong tradition in business and accounting programs. For someone who would go on to spend decades in life sciences finance, the emphasis on ethics alongside technical rigor in a Jesuit education isn't incidental.